Aldeyra Therapeutics, Inc. (137.F)
- Previous Close
3.6330 - Open
3.6440 - Bid 3.6520 x 31400
- Ask 3.7240 x 30200
- Day's Range
3.6430 - 3.6440 - 52 Week Range
1.3710 - 11.1300 - Volume
450 - Avg. Volume
335 - Market Cap (intraday)
217.661M - Beta (5Y Monthly) 1.52
- PE Ratio (TTM)
-- - EPS (TTM)
-0.6000 - Earnings Date May 2, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
25.45
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
www.aldeyra.comRecent News: 137.F
Performance Overview: 137.F
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 137.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 137.F
Valuation Measures
Market Cap
217.66M
Enterprise Value
99.12M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.94
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-2.82
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-16.23%
Return on Equity (ttm)
-27.73%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-37.54M
Diluted EPS (ttm)
-0.6000
Balance Sheet and Cash Flow
Total Cash (mrq)
142.82M
Total Debt/Equity (mrq)
13.07%
Levered Free Cash Flow (ttm)
-27.62M
Research Analysis: 137.F
Company Insights: 137.F
137.F does not have Company Insights